Physician profile
Patrick Pinchinat
NPI 1295946002
$15,258.77
in general payments reported to CMS, 2019-2025
31 companies · $3,908 in 2025
The $3,908 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,604 · 2020: $1,205 · 2021: $1,497 · 2022: $1,927 · 2023: $2,377 · 2024: $2,739 · 2025: $3,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,920 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,919.62 |
| Education | $105.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,200.03 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,611.20 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $1,311.61 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,216.40 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $1,010.58 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $964.37 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $913.88 | 2019-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $872.20 | 2019-2022 | |
| Lundbeck LLC | $870.32 | 2019-2025 | Rexulti |
| Almatica Pharma LLC | $800.68 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Janssen Pharmaceuticals, INC | $738.97 | 2019-2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $513.38 | 2022-2025 | Auvelity |
| Allergan, INC. | $450.15 | 2019-2020 | |
| Indivior INC. | $381.77 | 2019-2024 | Perseris, Sublocade |
| Supernus Pharmaceuticals, INC. | $368.80 | 2021-2025 | Qelbree, Qelbree |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $320.91 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $99.81 | 2022-2023 | Quviviq |
| Bausch Health US, LLC | $86.21 | 2019-2022 | |
| Neuronetics, INC. | $73.10 | 2019 | |
| Avanir Pharmaceuticals, INC. | $68.42 | 2019-2022 | |
| Orexo US, INC. | $58.28 | 2019-2021 | |
| Corium, LLC | $49.86 | 2023-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $47.04 | 2025 | Jornay Pm |
| Luye Pharma (USA) LTD. | $46.43 | 2025 | Erzofri Extended-Release |
| Takeda Pharmaceuticals U.S.A., INC. | $44.42 | 2021 | |
| Acadia Pharmaceuticals INC | $40.92 | 2019-2023 | Nuplazid |
| Ironshore Pharmaceuticals INC. | $21.22 | 2019 | |
| Biogen, INC. | $21.16 | 2025 | Zurzuvae |
| Tris Pharma INC | $20.12 | 2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $20.00 | 2022 | |
| Neos Therapeutics, LP | $16.53 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Pinchinat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.